Company: RDPTF
Filing Date: 2025-09-18
Form Type: 20-F
Source: 0001213900-25-088699
Chunk: 129

Company: Radiopharm Theranostics Ltd
Filing Date: 2025-09-18
Form: 20-F
Item: Item 8
Chunk 129
---
 of five years following the date of the last-to-expire patent right, whose expiration date is expected to be March 13,
2037 and the achievement of all milestone and completion of payments due. The agreement will be terminated if the license agreement between
Diaprost and Memorial Sloan Kettering Cancer Center is terminated. Diaprost retained the right to terminate the sublicense if Radiopharm
does not achieve certain milestones within the time specified in the agreement. The parties retain the right to terminate the agreement
for cause, and Radiopharm retains the right to terminate the agreement at will upon delivery of prior written 90-day notice.

Amendment to License Agreement with Diaprost and Fredax

In March 2025, Radiopharm
signed an amendment with Diaprost and Fredax to increase the payment of Milestone Event 4 to US$12,500,000 which US$11,750,000 will be
payable in cash and US$750,000 will be payable in shares of Radiopharm. All other amendments were minor in nature and had no monetary
value.

License Agreement with Cancer Research Technology

In October 2021, Radiopharm
entered into a license agreement with Cancer Research Technology Limited (“ CRT”) for the18F-FPIA Imaging Agent.
Under the terms of the agreement, Radiopharm was granted the exclusive, sublicensable, world-wide and royalty-bearing right to develop
and commercialize18F-FPIA Imaging Agent in the field of diagnosis, imaging, prevention and treatment of disease relating and
know-how that related to the licensed patents.

Radiopharm shall pay CRT up
to £35.8 million upon achievement of the certain development milestones and single-digit royalty rates on net sales of products
covered by the licensed rights. Radiopharm paid £180,000 as upfront fees.

The agreement will expire
on a country-by-country and licensed product-by-licensed product basis on the latter of (i) the date on which all valid claims covering
the licensed products are expired, finally revoked, withdrawn, abandoned or finally disallowed, in each case, without the possibility
of appeal or refiling of the claim, and expiry of the fifth year after the last to expire patents or five years after expiring of any
exclusivity, or price, reimbursement protection; or (ii) ten years after the first commercial sale of a licensed product. The expected
expiry date of the last-to-expire patent is 2035. The agreement